Andreas Brückner

Andreas Brückner

Novartis Institutes for BioMedical Research - Bhubaneswar / United States
Natural Sciences / Mathematical Sciences
AD Scientific Index ID: 4390969
-
person_outline Andreas Brückner's MOST POPULAR ARTICLES
1-) Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?D Strumberg, A Awada, H Hirte, JW Clark, S Seeber, P Piccart, E Hofstra, ...European Journal of Cancer 42 (4), 548-556, 20062242006
2-) Good signal detection practices: evidence from IMI PROTECTAFZ Wisniewski, A Bate, C Bousquet, A Brueckner, G Candore, K Juhlin, ...Drug safety 39 (6), 469-490, 2016992016
3-) Short-term acetylsalicylic acid (aspirin) use for pain, fever, or colds—gastrointestinal adverse effects: a meta-analysis of randomized clinical trialsA Lanas, D McCarthy, M Voelker, A Brueckner, S Senn, JA BaronDrugs in R & D 11, 277-288, 2011622011
4-) Development and validation of a risk-score model for subjects with impaired glucose tolerance for the assessment of the risk of type 2 diabetes mellitus—The STOP-NIDDM risk-scoreJ Tuomilehto, J Lindström, M Hellmich, W Lehmacher, T Westermeier, ...Diabetes research and clinical practice 87 (2), 267-274, 2010682010
5-) Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysisG Procopio, J Bellmunt, J Dutcher, S Bracarda, J Knox, A Brueckner, ...British journal of cancer 108 (2), 311-318, 2013562013